华检医疗(01931)发布中期业绩，股东应占溢利3911.9万元

Group 1 - The company reported a revenue of 1.27 billion and a profit attributable to shareholders of 39.12 million for the six months ending June 30, 2025 [1] - Adjusted profit was 35.63 million, with earnings per share at 2.41 cents [1] - The company aims to expand its technological innovation boundaries while consolidating its core IVD business, focusing on robotics and cutting-edge technologies to seize growth opportunities from global technological changes [1] Group 2 - The company plans to leverage capital markets to strengthen its leading position in China's IVD industry and adopt proactive development strategies [1]